Roth Capital analyst Jonathan Aschoff lowered the firm’s price target on Moleculin Biotech (MBRX) to $31 from $300 and keeps a Buy rating on the shares following the 1-for-25 reverse stock split. The firm says enrollment in the Phase2b/3 MIRACLE trial is progressing as anticipated, with initial results expected in Q1 of 2026.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MBRX:
- Moleculin Biotech target adjusted to $22 from $4 at H.C. Wainwright
- Promising Progress in Moleculin Biotech’s Phase 3 MIRACLE Study Boosts Buy Rating
- Moleculin Biotech Enters Inducement Offer Agreements
- Moleculin Biotech Updates on MIRACLE Study Progress
- Moleculin Biotech provides update on enrollment for MIRACLE study